Doctors at Northwestern Memorial Hospital are the first in Illinois to offer a new treatment for atrial fibrillation, a heart ...

Key points A 68-year-old woman from rural Ontario arrived at her local emergency department with worsening palpitations. Her medical history included breast cancer treated with surgical resection and ...

When pharmacists practice in value-based care settings, their impact on arrhythmia management expands far beyond medication ...

Ken’s search for answers brought him to nearly a dozen doctors. After months of tests, he was finally diagnosed with a rare ...

Cardiologists often struggle to assess heart attack risk. New startups using AI could help.

Novo Nordisk’s oral semaglutide Rybelsus reduced the risk for major adverse cardiovascular events by 14% in people with type ...

As competitors have launched their first pulsed field ablation devices in the U.S., Abbott CEO Robert Ford told investors ...

Stereotaxis CEO David Fischel said the precision, stability and safety profile of robotics are a good fit for pulsed field ...

Rhythio Medical announced today that it received FDA breakthrough device designation for its Injectable Electrode System.

Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in high-risk adults with type 2 diabetes.Approval of oral semaglutide ...

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...